Clinical Trials Using Cisplatin

Clinical trials are research studies that involve people. The clinical trials on this list are studying Cisplatin. All trials on the list are supported by NCI.

NCI’s basic information about clinical trials explains the types and phases of trials and how they are carried out. Clinical trials look at new ways to prevent, detect, or treat disease. You may want to think about taking part in a clinical trial. Talk to your doctor for help in deciding if one is right for you.

Trials 176-190 of 190
< Previous 1 ... 6 7 8

  • A Safety and Efficacy Study of INC280 Alone, and in Combination With Erlotinib, Compared to Chemotherapy, in Advanced / Metastatic Non-small Cell Lung Cancer Patients With EGFR Mutation and cMET Amplification

    The purpose of this study is to determine the maximum tolerated dose (MTD) or recommended phase II dose (RP2D) of INC280 in combination with erlotinib in the Phase Ib of this study, and to assess the anti-tumor activity and safety of INC280 alone, and in combination with erlotinib, versus platinum with pemetrexed in the Phase II of this study, in adult patients with EGFR mutated, cMET amplified, advanced / metastatic non-small cell lung cancer with acquired resistance to prior EGFR TKI.
    Location: University of California San Diego, San Diego, California

  • Tri-weekly Cisplatin Based Chemoradiation in Locally Advanced Cervical Cancer

    Current standard treatment for locally advanced cervical cancer is cisplatin-based concurrent chemoradiation (CRT). Although recently reported meta-analysis studies also demonstrated improved local control rates and survival with cisplatin-based chemotherapy concurrent to radiation therapy (RT), the optimal cisplatin dose and dosing schedule are still undetermined. In light of the results of the previous clinical trial, weekly cisplatin 40 mg / m2 considered to be a standard regiment in cisplatin doses and dosing schedules. However, our randomized phase II trial showed that tri-weekly cisplatin 75mg / m2 has lower toxicities and a better outcome in locally advanced cervical cancer. In this randomized phase III trial, the investigators investigate that there may be a survival difference between weekly cisplatin 40 mg / m2 and tri-weekly cisplatin 75 mg / m2 administration concurrent to RT in cervical cancer.
    Location: See Clinical Trials.gov

  • Gemcitabine Hydrochloride, Cisplatin, and Ipilimumab as First-Line Therapy in Treating Patients With Metastatic Urothelial Cancer

    This phase II clinical trial studies how well gemcitabine hydrochloride, cisplatin, and ipilimumab work as first-line therapy in treating patients with metastatic urothelial cancer. Drugs used in chemotherapy, such as gemcitabine hydrochloride and cisplatin, work in different ways to stop the growth of tumor cells, either by killing the cells or by stopping them from dividing. Monoclonal antibodies, such as ipilimumab, can block tumor growth in different ways. Some block the ability of tumors to grow and spread. Other find tumor cells and help kill them or carry tumor-killing substances to them. Giving gemcitabine hydrochloride and cisplatin together with ipilimumab may kill more tumor cells.
    Location: See Clinical Trials.gov

  • Pembrolizumab with or without Chemotherapy Before Surgery in Treating Patients with Stage I-IIIA Non-Small Cell Lung Cancer

    This phase II trial studies how well pembrolizumab with or without chemotherapy works when given before surgery in treating patients with stage I-IIIA non-small cell lung cancer. Immunotherapy with pembrolizumab, may induce changes in body’s immune system and may interfere with the ability of tumor cells to grow and spread. Drugs used in chemotherapy, such as cisplatin and pemetrexed, work in different ways to stop the growth of tumor cells, either by killing the cells, by stopping them from dividing, or by stopping them from spreading. Giving pembrolizumab with or without chemotherapy may shrink the cancer prior to surgery and decrease the likelihood of the cancer returning following surgery.
    Location: UCSF Medical Center-Mount Zion, San Francisco, California

  • Durvalumab and Standard Chemotherapy before Surgery in Treating Patients with Variant Histology Bladder Cancer

    This phase II trial studies the side effects of durvalumab and chemotherapy before surgery in treating patients with variant histology bladder cancer. Immunotherapy with monoclonal antibodies, such as durvalumab, may induce changes in the body's immune system and may interfere with the ability of tumor cells to grow and spread. Drugs used in chemotherapy, such as methotrexate, vinblastine, doxorubicin, cisplatin, gemcitabine, and carboplatin, work in different ways to stop the growth of tumor cells, either by killing the cells, by stopping them from dividing, or by stopping them from spreading. Giving durvalumab in addition to standard chemotherapy may lead to better outcomes in patients with variant histology bladder cancer.
    Location: Stanford Cancer Institute Palo Alto, Palo Alto, California

  • Standard Chemotherapy and Radiation Therapy with or without Paclitaxel and Carboplatin in Treating HIV-Positive Women with Locally Advanced Cervical Cancer

    This phase II trial studies how well standard chemotherapy and radiation therapy given with or without paclitaxel and carboplatin work in treating human immunodeficiency virus (HIV)-positive women with cervical cancer that has spread to nearby tissue or lymph nodes. Drugs used in chemotherapy, such as cisplatin, paclitaxel and carboplatin, work in different ways to stop the growth of tumor cells, either by killing the cells, by stopping them from dividing, or by stopping them from spreading. Radiation therapy to the pelvis destroys potential cancer cells in the pelvic area and significantly reduces the risk of tumor recurrence in the pelvic area. It is not yet known if giving chemotherapy and radiation therapy with or without paclitaxel and carboplatin, may work better in treating HIV-positive patients with advanced cervical cancer.
    Location: Location information is not yet available.

  • Alpelisib, Cetuximab, and Cisplatin in Treating Patients with HPV-Associated Oropharyngeal Cancer That Can Be Removed by Surgery

    This phase I / II trial studies the side effects and best way to give alpelisib, cetuximab, and cisplatin and to see how well these drugs work in treating patients with human papillomavirus (HPV)-associated oropharyngeal cancer that can be removed by surgery. Drugs used in chemotherapy, such as alpelisib and cisplatin, work in different ways to stop the growth of tumor cells, either by killing the cells or by stopping them from dividing. Monoclonal antibodies, such as cetuximab, can block tumor growth in different ways. Some block the ability of tumor cells to grow and spread. Others find tumor cells and help kill them or carry tumor-killing substances to them. Giving alpelisib, cisplatin, and cetuximab together may kill more tumor cells.
    Location: 5 locations

  • Olaparib, Cediranib Maleate, and Standard Chemotherapy in Treating Patients with Small Cell Lung Cancer

    This phase II trial studies how well olaparib, cediranib maleate, and standard chemotherapy work in treating patients with small cell lung cancer. Drugs used in chemotherapy, such as carboplatin, cisplatin, and etoposide, work in different ways to stop the growth of tumor cells, either by killing the cells, by stopping them from dividing, or by stopping them from spreading. Olaparib and cediranib maleate may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth. Olaparib, cediranib maleate, and standard chemotherapy may work better in treating patients with small cell lung cancer.
    Location: 23 locations

  • Pembrolizumab in Treating Patients with Malignant Pleural Mesothelioma That Can Be Removed by Surgery

    This pilot phase I trial studies pembrolizumab in treating patients malignant pleural mesothelioma that can be removed by surgery. Monoclonal antibodies, such as pembrolizumab, may interfere with the ability of tumor cells to grow and spread.
    Location: University of Chicago Comprehensive Cancer Center, Chicago, Illinois

  • Cetuximab and Radiation Therapy in Treating Patients with Stage III-IV Head and Neck Cancer

    This early phase I pilot trial studies cetuximab and radiation therapy in treating patients with stage III-IV head and neck cancer. Monoclonal antibodies, such as cetuximab, may block tumor growth in different ways by targeting certain cells. Radiation therapy uses high energy x rays to kill tumor cells. Drugs used in chemotherapy, such as cisplatin, work in different ways to stop the growth of tumor cells, either by killing the cells, by stopping them from dividing, or by stopping them from spreading. Giving cetuximab or cisplatin together with radiation therapy may kill more tumor cells.
    Location: 2 locations

  • Radiation Therapy with Cisplatin, Docetaxel, or Cetuximab and Docetaxel after Surgery in Treating Patients with High-Risk Stage III-IV Squamous Cell Head and Neck Cancer

    This randomized phase II / III trial studies how well radiation therapy works when given together with cisplatin, docetaxel or cetuximab and docetaxel after surgery in treating patients with high-risk stage III-IV head and neck cancer the begins in the thin, flat cells (squamous cell). Specialized radiation therapy that delivers a high dose of radiation directly to the tumor may kill more tumor cells and cause less damage to normal tissue. Drugs used in chemotherapy, such as cisplatin and docetaxel, work in different ways to stop the growth of tumor cells, either by killing the cells or by stopping them from dividing. Cetuximab may block the growth of tumor cells by blocking a protein and many other tumor cells functions. It is not yet known whether radiation therapy is more effective when given with cisplatin, docetaxel, or cetuximab and docetaxel.
    Location: 168 locations

  • Safety and Efficacy of RRx-001 in the Attenuation of Oral Mucositis in Patients Receiving Chemoradiation for the Treatment of Oral Cancers

    The purpose of this study is to determine if RRx-001, which is added on to the cisplatin and radiation treatment, reduces the duration or length of severe oral mucositis in patients with head and neck cancers. All patients in this study will receive 7 weeks of standard of care radiation therapy given with the chemotherapy agent, cisplatin. Patients in arms 1, 2 and 3 will also receive RRx-001 on different schedules.
    Location: 4 locations

  • Pulmonary Suffusion in Controlling Minimal Residual Disease in Patients with Soft Tissue or Bone Sarcoma Metastatic to the Lungs

    This phase I / II trial studies the side effects of pulmonary suffusion in controlling minimal residual disease in patients with soft tissue or bone sarcoma that has spread to the lungs. Pulmonary suffusion is a minimally invasive delivery of chemotherapeutic agents like cisplatin to lung tissues. Drugs used in chemotherapy, such as cisplatin, work in different ways to stop the growth of tumor cells, either by killing the cells, by stopping them from dividing, or by stopping them from spreading. Pulmonary suffusion may also be useful in avoiding later use of drugs by vein that demonstrate no effect on tumors when delivered locally.
    Location: Roswell Park Cancer Institute, Buffalo, New York

  • Pre-treatment Biopsy Results in Predicting Response in Patients with Metastatic or Recurrent Triple Negative Breast Cancer after Treatment with Cisplatin and Radiation Therapy

    This phase II trial studies how well the results of a pre-treatment biopsy work in predicting response in patients with triple negative breast cancer that has spread to other parts of the body (metastatic) or has come back after treatment (recurrent) with cisplatin and radiation therapy. A biopsy is where a tissue is removed from the body and examined under a microscope to determine whether disease is present. Studying tissue collected during pre-treatment biopsies in the laboratory may help determine the ability of the tumor to repair itself after being treated with chemotherapy (cisplatin) and radiation therapy and predict how well these treatments work for future patients with triple negative breast cancer.
    Location: 7 locations

  • A Study Of PF-05212384 In Combination With Other Anti-Tumor Agents and in Combination With Cisplatin in Patients With Triple Negative Breast Cancer in an Expansion Arm (TNBC)

    This study will evaluate PF-05212384 (gedatolisib) PI3K / mTOR inhibitor)) in combination with either docetaxel, cisplatin or dacomitinib in select advanced solid tumors. The study will assess the safety, pharmacokinetics and pharmacodynamics of these combinations in patients with advanced cancer in order to determine the maximum tolerated dose in each combination. The cisplatin combination expansion portion will evaluate the anti tumor activity of PF 05212384 plus cisplatin in patients with TNBC in 2 separate Arms (Arm 1 and Arm 2).
    Location: See Clinical Trials.gov


< Previous 1 ... 6 7 8